Literature DB >> 22378150

NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones.

Hong Liao1, Qian Zhou, Zhenbo Zhang, Qianqian Wang, Yunyan Sun, Xiaofang Yi, Youji Feng.   

Abstract

Aberrant nuclear factor-erythroid 2 (NRF2) expression correlates with tumor development. We investigated NRF2 expression in ovarian epithelial carcinoma (OEC), aiming to identify associations with clinicopathological factors, hormones and induced reactive oxygen species (ROS). Immunohistochemical staining for NRF2 expression was performed on 10 benign cystadenomas, 4 boderline tumors and 64 OECs. Western blotting was used to determine the effects of hormones on NRF2 expression in OEC. NRF2 protein was found to be overexpressed in OEC. Gonadotrophins and estrogen induced ROS production in OEC; these hormones also enhanced NRF2 expression. Therefore, aberrant expression may be induced by hormones through ROS signaling. Increased NRF2 expression may be a molecular event in OEC carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378150     DOI: 10.3892/or.2012.1700

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.

Authors:  Monique G P van der Wijst; Christian Huisman; Archibold Mposhi; Gerard Roelfes; Marianne G Rots
Journal:  Mol Oncol       Date:  2015-03-19       Impact factor: 6.603

2.  Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.

Authors:  Phui-Ly Liew; Chun-Sen Hsu; Wei-Min Liu; Yu-Chieh Lee; Yi-Chih Lee; Chi-Long Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Nuclear Factor Erythroid 2-Related Factor 2 Deficiency Results in Amplification of the Liver Fat-Lowering Effect of Estrogen.

Authors:  Wenjuan Rui; Yuhong Zou; Joonyong Lee; Shashank Manohar Nambiar; Jingmei Lin; Linjie Zhang; Yan Yang; Guoli Dai
Journal:  J Pharmacol Exp Ther       Date:  2016-05-09       Impact factor: 4.030

4.  Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

Authors:  J Chen; M Bai; C Ning; B Xie; J Zhang; H Liao; J Xiong; X Tao; D Yan; X Xi; X Chen; Y Yu; R C Bast; Z Zhang; Y Feng; W Zheng
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

5.  Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.

Authors:  Victor D Martinez; Emily A Vucic; Kelsie L Thu; Larissa A Pikor; Roland Hubaux; Wan L Lam
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

6.  Expression and correlation of NRF2, KEAP1, NQO-1 and HO-1 in advanced squamous cell carcinoma of the larynx and their association with clinicopathologic features.

Authors:  Changjiang Li; Haitao Wu; Shuyi Wang; Jiaxing Zhu
Journal:  Mol Med Rep       Date:  2016-11-01       Impact factor: 2.952

7.  Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women.

Authors:  Maha Ah Sulaiman; Yahya M Al-Farsi; Maha M Al-Khaduri; Jumana Saleh; Mostafa I Waly
Journal:  Int J Womens Health       Date:  2018-11-28

8.  Correlation of NQO1 and Nrf2 in Female Genital Tract Cancer and Their Precancerous Lesions (Cervix, Endometrium and Ovary).

Authors:  Nisreen Abdel Tawab Abdel Gaber Osman; Nehad M R Abd El-Maqsoud; Saad Abdelnaby A El Gelany
Journal:  World J Oncol       Date:  2015-06-12

Review 9.  Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities.

Authors:  Byung-Jin Jung; Hwan-Sic Yoo; Sooyoung Shin; Young-Joon Park; Sang-Min Jeon
Journal:  Biomol Ther (Seoul)       Date:  2018-01-01       Impact factor: 4.634

10.  Establishment of a SVM classifier to predict recurrence of ovarian cancer.

Authors:  Jinting Zhou; Lin Li; Liling Wang; Xiaofang Li; Hui Xing; Li Cheng
Journal:  Mol Med Rep       Date:  2018-08-08       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.